We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-11.11%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$7.07B
AUM Growth
-$1.54B
Cap. Flow
-$210M
Cap. Flow %
-2.97%
Top 10 Hldgs %
34.72%
Holding
187
New
10
Increased
57
Reduced
82
Closed
15

Top Buys

Rank Stock Value
1
ISRG icon
Intuitive Surgical
ISRG
+$67.9M
2
PFE icon
Pfizer
PFE
+$40.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$26.9M
4
HRMY icon
Harmony Biosciences
HRMY
+$26M
5
CRL icon
Charles River Laboratories
CRL
+$25.6M

Top Sells

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$100M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$81.4M
3
ABBV icon
AbbVie
ABBV
+$47.5M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$47.2M
5
BMY icon
Bristol-Myers Squibb
BMY
+$45.9M

Sector Composition

Rank Sector Weight
1 Healthcare 98.26%
2 Industrials 0.38%
3 Energy 0.03%
4 Communication Services 0.01%
5 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TXG icon
101
10x Genomics
TXG
$5.49B
$11.7M 0.17%
259,371
+6,512
+3% +$338K
NVRO
102
DELISTED
NEVRO CORP.
NVRO
$11.6M 0.16%
265,339
+27,498
+12% +$1.51M
BDTX icon
103
Black Diamond Therapeutics
BDTX
$104M
$11.6M 0.16%
4,717,113
+1,424,113
+43% +$3.31M
REGN icon
104
Regeneron Pharmaceuticals
REGN
$70.5B
$10.5M 0.15%
17,727
-72,553
-80% -$47.2M
MTEM
105
DELISTED
Molecular Templates, Inc.
MTEM
$10.3M 0.15%
751,867
+13,333
+2% +$312K
SGEN
106
DELISTED
Seagen Inc. Common Stock
SGEN
$8.74M 0.12%
49,376
-1,024
-2% -$148K
AMWL icon
107
American Well
AMWL
$210M
$7.64M 0.11%
88,485
– –
ONEM
108
DELISTED
1Life Healthcare
ONEM
$6.56M 0.09%
836,190
– –
HCAT icon
109
Health Catalyst
HCAT
$160M
$6.15M 0.09%
424,611
– –
BMRN icon
110
BioMarin Pharmaceuticals
BMRN
$11.4B
$6.11M 0.09%
73,753
-847
-1% -$67.4K
AZN icon
111
AstraZeneca
AZN
$255B
$5.75M 0.08%
43,500
-1,300
-3% -$171K
JNJ icon
112
Johnson & Johnson
JNJ
$599B
$5.13M 0.07%
28,914
+1,214
+4% +$216K
DOCS icon
113
Doximity
DOCS
$3.91B
$4.75M 0.07%
136,322
+53,462
+65% +$2.1M
GILD icon
114
Gilead Sciences
GILD
$165B
$4.66M 0.07%
75,426
-8,024
-10% -$497K
BIIB icon
115
Biogen
BIIB
$29.5B
$4.46M 0.06%
21,850
-500
-2% -$102K
OLK
116
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$3.58M 0.05%
235,273
– –
QTTB icon
117
Q32 Bio
QTTB
$346M
$3.2M 0.05%
90,140
-1,367
-1% -$46.7K
ALKS icon
118
Alkermes
ALKS
$8.62B
$3.19M 0.05%
107,200
+32,200
+43% +$925K
PCRX icon
119
Pacira BioSciences
PCRX
$997M
$3.03M 0.04%
51,936
+30,800
+146% +$2.02M
GH icon
120
Guardant Health
GH
$19.6B
$2.85M 0.04%
70,580
-139,132
-66% -$6.89M
SGHT icon
121
Sight Sciences
SGHT
$274M
$2.65M 0.04%
294,606
-5,394
-2% -$47.5K
CYTK icon
122
Cytokinetics
CYTK
$10.7B
$2.61M 0.04%
66,400
-2,600
-4% -$105K
LUNG icon
123
Pulmonx
LUNG
$57M
$2.55M 0.04%
173,336
-3,174
-2% -$65.4K
NPCE icon
124
Neuropace
NPCE
$537M
$2.51M 0.04%
507,930
– –
SUPN icon
125
Supernus Pharmaceuticals
SUPN
$2.75B
$2.38M 0.03%
82,400
+23,400
+40% +$670K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2022 Portfolio in Review

As of Q2 2022, Bellevue Group held 187 positions worth $7.07B, down 18% from $8.61B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Bellevue Group's Q2 2022 filing shows 10 new, 57 increased, 82 reduced and 15 closed positions. Its largest new stake was Celldex Therapeutics: 925,000 shares worth $24.9M. The largest sale was Elevance Health, an estimated $100M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Industrials and Energy.

  • Bellevue Group's largest Q2 2022 buy was Celldex Therapeutics: 925,000 shares worth $24.9M.
  • Bellevue Group added most to Intuitive Surgical in Q2 2022, an estimated $67.9M increase.
  • Bellevue Group's biggest Q2 2022 reduction was Elevance Health, cutting an estimated $100M.
  • Bellevue Group fully exited Dentsply Sirona in Q2 2022, selling an estimated $7.83M.
  • Bellevue Group's ten largest holdings make up 35% of its $7.07B portfolio in Q2 2022.
  • Bellevue Group opened 10 new positions and closed 15 in Q2 2022.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $7.07B.

Based on Bellevue Group's 13F filing for Q2 2022, filed 11 Aug 2022.